| 查看: 632 | 回复: 6 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
sgh_119至尊木虫 (职业作家)
|
[交流]
【Pure water】First human trial of embryonic stem cells
|
||
|
US doctors have begun the first official trial of using human embryonic stem cells in patients after getting the green light from regulators. The Food and Drug Administration has given a license to Geron to use the controversial cells to treat people with spinal injuries. The cells have the potential to become many of the different cell types found in the body, including nerve cells. The trials at a hospital in Atlanta will check if the treatment is safe. Pivotal research Geron, a biotech company based in "silicon valley" south of San Francisco, has spent $170m on developing a stem cell treatment for spinal cord injury. The research will use cells coaxed to become nerve cells which are injected into the spinal cord. In animal trials of the treatment, paralysed rats regained some movement. But it is not yet known if it will offer any benefit to people with spinal cord injuries. Every year around 12,000 people in the US sustain spinal cord injuries. The most common causes are automobile accidents, falls, gunshot wounds and sports injuries. In the trial, patients who have sustained such an injury within the last 14 days will be given the experimental stem cell treatment. Geron president Dr Thomas Okarma said: "When we started working with human embryonic stem cells in 1999, many predicted that it would be a number of decades before a cell therapy would be approved for human clinical trials. "This accomplishment results from extensive research and development and a succession of inventive steps." But it will take some time to get the results. And there are many years of rigorous testing ahead before it can be known if the therapy is safe and effective. Professor Sir Ian Wilmut, director of the Medical Research Council Centre for Regenerative Medicine at the University of Edinburgh, said: "This is very exciting news, however, it is very important to appreciate that the objective of trials at this stage is to confirm first of all that no harm is done to patients, rather than to look for benefits. "Once that has been confirmed then the focus moves on to development and assessment of the new treatment." Ben Sykes, executive director of the UK National Stem Cell Network, said: "This is indeed a significant milestone in our journey towards the promise of stem cell-based medicines. "The global stem cell and regenerative medicine community will be awaiting the results of this safety trial with much anticipation." |
回复此楼» 猜你喜欢
论文终于录用啦！满足毕业条件了
已经有21人回复
-
不自信的我
已经有5人回复
-
磺酰氟产物，毕不了业了！
已经有4人回复
-
投稿Elsevier的杂志（返修），总是在选择OA和subscription界面被踢皮球
已经有8人回复
★
小木虫(金币+0.2):抢了个小板凳，给个红包
小木虫(金币+0.2):抢了个小板凳，给个红包
 |
3楼2010-10-12 07:20:55